Header Logo

Connection

Changmeng Cai to Receptors, Androgen

Back to Details
This is a "connection" page, showing publications Changmeng Cai has written about Receptors, Androgen.
Changmeng Cai
Connection Strength
8.708
Receptors, Androgen
  1. Han D, Labaf M, Zhao Y, Owiredu J, Zhang S, Patel K, Venkataramani K, Steinfeld JS, Han W, Li M, Liu M, Wang Z, Besschetnova A, Patalano S, Mulhearn MJ, Macoska JA, Yuan X, Balk SP, Nelson PS, Plymate SR, Gao S, Siegfried KR, Liu R, Stangis MM, Foxa G, Czernik PJ, Williams BO, Zarringhalam K, Li X, Cai C. Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs. J Clin Invest. 2024 Apr 30; 134(11).
    View in: PubMed
    Score: 0.802
  2. Han W, Liu M, Han D, Toure AA, Li M, Besschetnova A, Wang Z, Patalano S, Macoska JA, Lam HM, Corey E, He HH, Gao S, Balk SP, Cai C. Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer. Mol Ther. 2022 04 06; 30(4):1628-1644.
    View in: PubMed
    Score: 0.687
  3. Han D, Chen S, Han W, Gao S, Owiredu JN, Li M, Balk SP, He HH, Cai C. ZBTB7A Mediates the Transcriptional Repression Activity of the Androgen Receptor in Prostate Cancer. Cancer Res. 2019 10 15; 79(20):5260-5271.
    View in: PubMed
    Score: 0.580
  4. Han D, Gao S, Valencia K, Owiredu J, Han W, de Waal E, Macoska JA, Cai C. A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer. Oncotarget. 2017 Jan 24; 8(4):6796-6808.
    View in: PubMed
    Score: 0.485
  5. Gao S, Gao Y, He HH, Han D, Han W, Avery A, Macoska JA, Liu X, Chen S, Ma F, Chen S, Balk SP, Cai C. Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein. Cell Rep. 2016 10 18; 17(4):966-976.
    View in: PubMed
    Score: 0.476
  6. Gao S, Ye H, Gerrin S, Wang H, Sharma A, Chen S, Patnaik A, Sowalsky AG, Voznesensky O, Han W, Yu Z, Mostaghel EA, Nelson PS, Taplin ME, Balk SP, Cai C. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer. Clin Cancer Res. 2016 07 15; 22(14):3672-82.
    View in: PubMed
    Score: 0.456
  7. Cai C, He HH, Gao S, Chen S, Yu Z, Gao Y, Chen S, Chen MW, Zhang J, Ahmed M, Wang Y, Metzger E, Sch?le R, Liu XS, Brown M, Balk SP. Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity. Cell Rep. 2014 Dec 11; 9(5):1618-1627.
    View in: PubMed
    Score: 0.418
  8. Cai C, Wang H, He HH, Chen S, He L, Ma F, Mucci L, Wang Q, Fiore C, Sowalsky AG, Loda M, Liu XS, Brown M, Balk SP, Yuan X. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. J Clin Invest. 2013 Mar; 123(3):1109-22.
    View in: PubMed
    Score: 0.369
  9. Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, Chen S, Nelson PS, Liu XS, Brown M, Balk SP. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell. 2011 Oct 18; 20(4):457-71.
    View in: PubMed
    Score: 0.336
  10. Cai C, Balk SP. Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer. 2011 Oct; 18(5):R175-82.
    View in: PubMed
    Score: 0.333
  11. Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon NI, Wang H, Chen S, Balk SP. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 2011 Oct 15; 71(20):6503-13.
    View in: PubMed
    Score: 0.333
  12. Cai C, Portnoy DC, Wang H, Jiang X, Chen S, Balk SP. Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2. Cancer Res. 2009 Jun 15; 69(12):5202-9.
    View in: PubMed
    Score: 0.285
  13. Cai C, Hsieh CL, Shemshedini L. c-Jun has multiple enhancing activities in the novel cross talk between the androgen receptor and Ets variant gene 1 in prostate cancer. Mol Cancer Res. 2007 Jul; 5(7):725-35.
    View in: PubMed
    Score: 0.250
  14. Cai C, Hsieh CL, Omwancha J, Zheng Z, Chen SY, Baert JL, Shemshedini L. ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Mol Endocrinol. 2007 Aug; 21(8):1835-46.
    View in: PubMed
    Score: 0.248
  15. Jamroze A, Liu X, Hou S, Jess Li W, Yu H, Tracz A, Jacobi J, Li Q, Nastiuk K, Chen X, Huang J, Lin K, Liu M, Cai C, Lu Y, Puzanov I, Kirk JS, Chatta G, Tang DG. Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer. Signal Transduct Target Ther. 2026 May 01; 11(1).
    View in: PubMed
    Score: 0.230
  16. Wang Z, Townley SL, Zhang S, Liu M, Li M, Labaf M, Patalano S, Venkataramani K, Siegfried KR, Macoska JA, Han D, Gao S, Risbridger GP, Taylor RA, Lawrence MG, He HH, Selth LA, Cai C. FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer. Nat Commun. 2024 Jun 08; 15(1):4914.
    View in: PubMed
    Score: 0.202
  17. Wang Z, Petricca J, Liu M, Zhang S, Chen S, Li M, Besschetnova A, Patalano S, Venkataramani K, Siegfried KR, Macoska JA, Han D, Gao S, Vedadi M, Arrowsmith CH, He HH, Cai C. SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1. Proc Natl Acad Sci U S A. 2023 08 15; 120(33):e2220472120.
    View in: PubMed
    Score: 0.191
  18. Li M, Liu M, Han W, Wang Z, Han D, Patalano S, Macoska JA, Balk SP, He HH, Corey E, Gao S, Cai C. LSD1 Inhibition Disrupts Super-Enhancer-Driven Oncogenic Transcriptional Programs in Castration-Resistant Prostate Cancer. Cancer Res. 2023 05 15; 83(10):1684-1698.
    View in: PubMed
    Score: 0.188
  19. Han W, Liu M, Han D, Li M, Toure AA, Wang Z, Besschetnova A, Patalano S, Macoska JA, Gao S, He HH, Cai C. RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition. Oncogene. 2022 Feb; 41(6):852-864.
    View in: PubMed
    Score: 0.171
  20. Teng M, Zhou S, Cai C, Lupien M, He HH. Pioneer of prostate cancer: past, present and the future of FOXA1. Protein Cell. 2021 01; 12(1):29-38.
    View in: PubMed
    Score: 0.156
  21. Gao S, Chen S, Han D, Wang Z, Li M, Han W, Besschetnova A, Liu M, Zhou F, Barrett D, Luong MP, Owiredu J, Liang Y, Ahmed M, Petricca J, Patalano S, Macoska JA, Corey E, Chen S, Balk SP, He HH, Cai C. Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer. Nat Genet. 2020 10; 52(10):1011-1017.
    View in: PubMed
    Score: 0.156
  22. Gao S, Chen S, Han D, Barrett D, Han W, Ahmed M, Patalano S, Macoska JA, He HH, Cai C. Forkhead domain mutations in FOXA1 drive prostate cancer progression. Cell Res. 2019 Sep; 29(9):770-772.
    View in: PubMed
    Score: 0.144
  23. Nyquist MD, Corella A, Burns J, Coleman I, Gao S, Tharakan R, Riggan L, Cai C, Corey E, Nelson PS, Mostaghel EA. Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155. Mol Cancer Res. 2017 05; 15(5):521-531.
    View in: PubMed
    Score: 0.123
  24. Liu X, Gao Y, Ye H, Gerrin S, Ma F, Wu Y, Zhang T, Russo J, Cai C, Yuan X, Liu J, Chen S, Balk SP. Positive feedback loop mediated by protein phosphatase 1a mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer. Nucleic Acids Res. 2017 04 20; 45(7):3738-3751.
    View in: PubMed
    Score: 0.123
  25. Liu X, Han W, Gulla S, Simon NI, Gao Y, Cai C, Yang H, Zhang X, Liu J, Balk SP, Chen S. Protein phosphatase 1 suppresses androgen receptor ubiquitylation and degradation. Oncotarget. 2016 Jan 12; 7(2):1754-64.
    View in: PubMed
    Score: 0.113
  26. Chen EJ, Sowalsky AG, Gao S, Cai C, Voznesensky O, Schaefer R, Loda M, True LD, Ye H, Troncoso P, Lis RL, Kantoff PW, Montgomery RB, Nelson PS, Bubley GJ, Balk SP, Taplin ME. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015 Mar 15; 21(6):1273-80.
    View in: PubMed
    Score: 0.103
  27. Yu Z, Cai C, Gao S, Simon NI, Shen HC, Balk SP. Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor. Clin Cancer Res. 2014 Aug 01; 20(15):4075-85.
    View in: PubMed
    Score: 0.101
  28. Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, Nelson PS, Cai C, Balk SP. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res. 2014 Mar 15; 20(6):1590-600.
    View in: PubMed
    Score: 0.098
  29. Chen S, Gulla S, Cai C, Balk SP. Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation. J Biol Chem. 2012 Mar 09; 287(11):8571-83.
    View in: PubMed
    Score: 0.086
  30. Fang Z, Zhang T, Dizeyi N, Chen S, Wang H, Swanson KD, Cai C, Balk SP, Yuan X. Androgen Receptor Enhances p27 Degradation in Prostate Cancer Cells through Rapid and Selective TORC2 Activation. J Biol Chem. 2012 Jan 13; 287(3):2090-8.
    View in: PubMed
    Score: 0.085
  31. Cai C, Wang H, Xu Y, Chen S, Balk SP. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Res. 2009 Aug 01; 69(15):6027-32.
    View in: PubMed
    Score: 0.072
  32. Hsieh CL, Cai C, Giwa A, Bivins A, Chen SY, Sabry D, Govardhan K, Shemshedini L. Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells. J Mol Endocrinol. 2008 Jul; 41(1):13-23.
    View in: PubMed
    Score: 0.066
  33. Zheng Z, Cai C, Omwancha J, Chen SY, Baslan T, Shemshedini L. SUMO-3 enhances androgen receptor transcriptional activity through a sumoylation-independent mechanism in prostate cancer cells. J Biol Chem. 2006 Feb 17; 281(7):4002-12.
    View in: PubMed
    Score: 0.056
  34. Ma F, Chen S, Cecchi L, Ersoy-Fazlioglu B, Russo JW, Arai S, Awad S, Calagua C, Xie F, Poluben L, Voznesensky O, Ku AT, Karzai F, Cai C, Einstein DJ, Ye H, Yuan X, Toker A, Taplin ME, Sowalsky AG, Balk SP. Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion. J Clin Invest. 2025 12 01; 135(23).
    View in: PubMed
    Score: 0.055
  35. Berger N, Kugler B, Han D, Li M, Nguyen P, Anderson M, Patalano-Salsman S, Zhang S, Macoska J, Cai C, Zou K. Voluntary Exercise Attenuates Tumor Growth in a Preclinical Model of Castration-Resistant Prostate Cancer. Med Sci Sports Exerc. 2025 Aug 01; 57(8):1732-1742.
    View in: PubMed
    Score: 0.053
  36. Chen S, Cai C, Sowalsky AG, Ye H, Ma F, Yuan X, Simon NI, Gray NS, Balk SP. BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer. Cancer Res. 2018 09 15; 78(18):5203-5215.
    View in: PubMed
    Score: 0.034
  37. Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, Xu H, Cato L, Thornton JE, Gregory RI, Morrissey C, Vessella RL, Montironi R, Magi-Galluzzi C, Kantoff PW, Balk SP, Liu XS, Brown M. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science. 2012 Dec 14; 338(6113):1465-9.
    View in: PubMed
    Score: 0.023
  38. Shen HC, Shanmugasundaram K, Simon NI, Cai C, Wang H, Chen S, Balk SP, Rigby AC. In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer. Mol Endocrinol. 2012 Nov; 26(11):1836-46.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.